Comparative Pharmacology
Head-to-head clinical analysis: CORDRAN versus POKONZA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORDRAN versus POKONZA.
CORDRAN vs POKONZA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression to induce anti-inflammatory, antipruritic, and vasoconstrictive effects.
POKONZA (ponazuril) is a triazine antiprotozoal agent that inhibits the mitochondrial electron transport chain at the cytochrome bc1 complex, disrupting the parasite's energy metabolism and leading to its death. It is active against apicomplexan parasites such as Toxoplasma gondii, Neospora caninum, and Sarcocystis neurona.
Apply a thin layer to the affected skin areas once or twice daily. For CORDRAN Tape, apply tape to affected area once every 12 to 24 hours.
Intravenous: 0.1 mg/kg every 8 hours for 28 consecutive days per 6-week cycle.
None Documented
None Documented
Terminal half-life is approximately 7.5 hours (range 6-10 hours) in adults with normal hepatic function. This supports twined-daily dosing for dermatological indications.
Terminal elimination half-life 12-15 hours; clinically significant for once-daily dosing with steady-state achieved in 3-5 days
Primarily hepatic metabolism; metabolites excreted in urine and feces. Renal excretion of unchanged drug is negligible (<5%). Biliary/fecal excretion accounts for ~20% of metabolites.
Primarily renal excretion (70-80% unchanged drug); biliary/fecal elimination accounts for 15-20%
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid